AFM-11

N/A

Report date: 2026/03/19 16:46:41

Base Information

Drug NameAFM-11

Drug Alias NameAFM-11

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionCD3 T-cell engagersB-lymphocyte antigen CD19 inhibitors

TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3

Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaUnited StatesPoland +[7]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAffimed

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAffimed Gmbh

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellLeukemia, B-Cell

Other Information

ATC CodeN/A